NPORT-EX 2 NPORT_VEAI_99284619_0624.htm
VANECK
BIOTECH
ETF
SCHEDULE
OF
INVESTMENTS
June
30,
2024
(unaudited)
1
FootnoteRuleAboveBlank
Footnotes:
Number
of
Shares
Value
COMMON
STOCKS
:
100.0%
China
:
3.1%
BeiGene
Ltd.
(ADR) *
95,450
$
13,617,852
Underline
Germany
:
2.0%
BioNTech
SE
(ADR) *
108,659
8,731,837
Underline
Ireland
:
4.4%
ICON
Plc
(USD) *
60,789
19,055,528
Underline
Switzerland
:
1.0%
CRISPR
Therapeutics
AG
(USD) *
77,628
4,192,688
Underline
United
States
:
89.5%
Alnylam
Pharmaceuticals,
Inc. *
59,299
14,409,657
Amgen,
Inc.
213,907
66,835,242
Argenx
SE
(ADR) *
50,821
21,855,063
Biogen,
Inc. *
84,287
19,539,412
BioMarin
Pharmaceutical,
Inc. *
133,522
10,992,866
Bio-Techne
Corp.
142,209
10,189,275
Charles
River
Laboratories
International,
Inc. *
47,089
9,727,646
Cytokinetics,
Inc. *
59,126
3,203,447
Exact
Sciences
Corp. *
149,224
6,304,714
Gilead
Sciences,
Inc.
457,573
31,394,084
GRAIL
INC *
24,893
382,605
Illumina,
Inc. *
149,358
15,589,988
Incyte
Corp. *
147,575
8,945,996
IQVIA
Holdings,
Inc. *
99,324
21,001,067
Number
of
Shares
Value
United
States
(continued)
Moderna,
Inc. *
146,787
$
17,430,956
Natera,
Inc. *
105,064
11,377,381
Neurocrine
Biosciences,
Inc. *
90,818
12,502,914
QIAGEN
NV
212,555
8,733,885
Regeneron
Pharmaceuticals,
Inc. *
34,115
35,855,888
Repligen
Corp. *
45,185
5,696,021
Sarepta
Therapeutics,
Inc. *
80,870
12,777,460
Vertex
Pharmaceuticals,
Inc. *
92,069
43,154,582
387,900,149
Total
Common
Stocks
(Cost:
$441,199,990)
433,498,054
SHORT-TERM
INVESTMENT
HELD
AS
COLLATERAL
FOR
SECURITIES
ON
LOAN:
0.1%
Money
Market
Fund:
0.1%
(Cost:
$425,945)
State
Street
Navigator
Securities
Lending
Government
Money
Market
Portfolio
425,945
425,945
Total
Investments:
100.1%
(Cost:
$441,625,935)
433,923,999
Liabilities
in
excess
of
other
assets:
(0.1)%
(352,865)
NET
ASSETS:
100.0%
$
433,571,134
Definitions:
ADR
American
Depositary
Receipt
USD
United
States
Dollar
*
Non-income
producing
Security
fully
or
partially
on
loan.
Total
market
value
of
securities
on
loan
is
$8,640,265.